Patient-reported Symptom Experiences in Patients with Carcinoid Syndrome after Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach

Clinical Therapeutics

Volumn 38, Issue 4, 2016, Pages 759-768

  Gelhorn, Heather L ^a   Kulke, Matthew H ^b   O'Dorisio, Thomas ^c   Yang, Qi M ^d   Jackson, Jessica ^d   Jackson, Shanna ^d,e   Boehm, Kristi A ^d   Law, Linda ^d,f   Kostelec, Jacqueline ^a,f   Auguste, Priscilla ^a   Lapuerta, Pablo ^d  

^a EVIDERA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d LEXICON PHARMACEUTICALS INC   (United States)

^e Savara Pharmaceuticals   (United States)

^f Bio Health Consult ^*  (United States)

Author keywords

carcinoid syndrome; patient reported; qualitative; telotristat etiprate

Indexed keywords

TELOTRISTAT ETIPRATE; ANTINEOPLASTIC AGENT; PHENYLALANINE; PYRIMIDINE DERIVATIVE; TELOTRISTAT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CARCINOID SYNDROME; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITATIVE RESEARCH; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF REPORT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; INTERVIEW; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; DIARRHEA; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; PHENYLALANINE; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84961959051     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.03.002     Document Type: Article

References (17)

1. B.G. Taal, and O. Visser Epidemiology of neuroendocrine tumours Neuroendocrinology 80 Suppl 1 2004 3 7
2. Choti MA, Bobiak S, Strosberg JR, et al. Prevalence of functional tumors in neuroendocrine carcinoma: an analysis from the NCCN NET database. Presented at the 2012 Neuroendocrine Tumor Symposium; October 2012.
3. D. McCormick Carcinoid tumors and syndrome Gastroenterol Nurs 25 2002 105 111
4. I. Schnirer, J.C. Yao, and J.A. Ajani Carcinoid - a comprehensive review Acta Oncol 42 2003 672 692
5. M.H. Kulke, T. O'Dorisio, A. Phan, and et al. Evaluation of telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome not adequately controlled by octreotide Endocr Relat Cancer 21 2014 705 714
6. J.K. Ramage, and A.H. Davies Measurement of quality of life in carcinoid/neuroendocrine tumours Endocr Relat Cancer 10 2003 483 486
7. European Organization for Research and Treatment of Cancer. EORTC QOL module for carcinoid/neuroendocrine tumours: EORTC QLQ-G.I.NET21. http://groups.eortc.be/qol/carcinoid-neuroendocrine-tumours-qlq-ginet21. Accessed December 22, 2015.
8. EORTC QLQ-C30. http://groups.eortc.be/qol/eortc-qlq-c30. Accessed December 22, 2015.
9. T. Muhr, and S. Friese User's Manual for ATLAS.ti 5.0. 2nd ed 2004 Scientific Software Development Berlin
10. D.L. Patrick, L.B. Burke, C.J. Gwaltney, and et al. Content validity - establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1 - eliciting concepts for a new PRO instrument Value Health 14 2011 967 977
11. N.K. Leidy, and M. Vernon Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment Pharmacoeconomics 26 2008 363 370
12. Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 reference values. http://groups.eortc.be/qol/sites/default/files/img/newsletter/reference-values-manual2008.pdf. Accessed January 11, 2016.
13. P. Lapuerta, B. Zambrowicz, D. Fleming, and et al. Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome Clin Invest 5 2015 447 456
14. US Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. December 2009. http://www.fda.gov/downloads/Drugs/./Guidances/UCM193282.pdf. Accessed March 22, 2016.
15. G. Yadegarfar, L. Friend, L. Jones, et al. EORTC Quality of Life Group Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours Br J Cancer 108 2013 301 310
16. Curtis P, Slaughter-Mason S, Thielke A, et al. PCORI Expert Interviews Project Final Report. http://www.pcori.org/sites/default/files/ExpertInterviewsPart1.pdf. Accessed February 22, 2016.
17. MedlinePlus. 5-HIAA. http://www.nlm.nih.gov/medlineplus/ency/article/003612.htm. Accessed April 24, 2013.